Collaboration between Batavia Biosciences and UGA Biopharma
Both companies have the ambition to provide services and technologies supporting the development of high quality and affordable biopharmaceuticals. Through the partnership, two enzyme expressing monoclonal cell lines are now delivered. They were developed and validated by Batavia Biosciences using STEP® technology, and were guided by UGA Biopharma´s in-depth knowledge and experience in the development of cell lines for biosimilar and NBE drugs.
Dr. Frank Däbritz (Project Manager UGA) adds: “It was a pleasure to collaborate with Batavia Biosciences and to profit from the scientific experience of both companies to realize more successful projects in a short time”.